Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation-Reference-Cited by-同舟云学术

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation

Published:2020-12 Issue:12 Volume:27 Page:1500-1509.e13
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Zhang Jing,Fu Liqiang,Shen Bin,Liu Yingtao,Wang Wenqian,Cai Xin,Kong Linglong,Yan Yilin,Meng Ryan,Zhang Zhuming,Chen Ying-Nan P.,Liu Qian,Wan Zhao-Kui,Zhou Tianyuan^ORCID,Wang Xiaotao,Gavine Paul,Del Rosario Amanda^ORCID,Ahn Kay,Philippar Ulrike,Attar Ricardo,Yang Jennifer,Xu Yanping,Edwards James P.,Dai Xuedong

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference54 articles.

1. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function;Adachi;Immunity,1998

2. Toll-like receptor signaling pathways;Barton;Science,2003

3. The protein data bank;Berman;Nucleic Acids Res.,2000

4. RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy;Burley;Nucleic Acids Res.,2018

5. TRAF6 is a signal transducer for interleukin-1;Cao;Nature,1996

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications;European Journal of Medicinal Chemistry;2024-09

2. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions;Bioconjugate Chemistry;2024-07-11

3. Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma;Journal of Medicinal Chemistry;2024-06-26

4. Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury;Journal of Medicinal Chemistry;2024-06-24

5. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases;Journal of Medicinal Chemistry;2024-05-09